000043567 000__ 00904nam\a2200361\i\4500
000043567 001__ 43567
000043567 003__ SzGeWIPO
000043567 005__ 20240708150001.0
000043567 006__ m\\\\eo\\d\\\\\\\\
000043567 007__ cr bn |||m|||a
000043567 008__ 210511s2019\\\\enk\\\\\o\\\\\000\0\eng\d
000043567 022__ $$aOnline: 1747-1540
000043567 0247_ $$a10.1093/jiplp/jpz069$$2doi
000043567 035__ $$a(OCoLC)1255904481
000043567 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000043567 041__ $$aeng
000043567 1001_ $$aSignoroni, Stella Altea.
000043567 24500 $$aAbraxis: new pharmaceutical formulations and Article 3(d) SPC Regulation.
000043567 264_1 $$a[Oxford, England] :$$bOxford University Press (OUP),$$c2019
000043567 300__ $$a1 online resource (pages 511-512)
000043567 337__ $$acomputer$$2rdamedia
000043567 4901_ $$aJournal Of Intellectual Property Law & Practice,$$x1747-1540 ;$$v14, 7, 2019
000043567 542__ $$fhttps://academic.oup.com/jiplp/article/14/7/511/5524193
000043567 588__ $$aCrossref
000043567 590__ $$aPublished online: 27-Jun-19
000043567 650_0 $$aIntellectual property.
000043567 7731_ $$tJournal of Intellectual Property Law & Practice$$wjiplp
000043567 830_0 $$aJournal Of Intellectual Property Law & Practice ;$$v14, 7, 2019.
000043567 85641 $$uhttps://doi.org/10.1093/jiplp/jpz069$$yOnline version
000043567 904__ $$aJournal article
000043567 980__ $$aJIPLP